Clinical Trial: Re-Irradiation of Progressive or Recurrent DIPG

Study Status: Not yet recruiting
Recruit Status: Not yet recruiting
Study Type: Interventional

Official Title: ReRAD: A Phase II Canadian Pediatric Brain Tumour Consortium Study of Re-Irradiation as Treatment of Progressive or Recurrent Diffuse Intrinsic Pontine Glioma

Brief Summary: This is a single-arm, non-randomized study of re-irradiation of diffuse intrinsic pontine glioma (DIPG)

Detailed Summary: Study therapy will consist of radiation therapy (RT) given over 17 treatment days (for 30.6 Gy in fractions of 1.8 Gy) or 20 treatment days (for 36 Gy in 1.8 Gy fractions), depending on the time from completion of the first course of RT. Treatment days will generally be weekdays, not including statutory holidays.
Sponsor: University of Calgary

Current Primary Outcome: second progression-free survival [ Time Frame: up to 18 months from the start of re-irradiation ]

length of time from start of re-irradiation to subsequent progression of disease


Original Primary Outcome: Same as current

Current Secondary Outcome: overall survival [ Time Frame: up to three years from initial diagnosis of DIPG ]

time from initial diagnosis of DIPG to death following re-irradiation


Original Secondary Outcome: Same as current

Information By: University of Calgary

Dates:
Date Received: April 19, 2017
Date Started: June 1, 2017
Date Completion: October 2021
Last Updated: April 19, 2017
Last Verified: March 2017